[Hemorrhagic bullous dermatosis (HBD): A rare side-effect of heparins].

Dermatose bulleuse hémorragique (DBH) : un effet indésirable rare des héparines.

Journal

Annales de dermatologie et de venereologie
ISSN: 0151-9638
Titre abrégé: Ann Dermatol Venereol
Pays: France
ID NLM: 7702013

Informations de publication

Date de publication:
Historique:
received: 08 12 2018
revised: 04 02 2019
accepted: 21 08 2019
pubmed: 2 2 2020
medline: 28 5 2021
entrez: 2 2 2020
Statut: ppublish

Résumé

Bullous haemorrhagic dermatosis (BHD) induced by heparin is a rare and benign side effect of which we report two cases. Case 1: an 81-year-old man presented haemorrhagic bullae on the limbs and trunk 7 days after starting enoxaparin. The laboratory haemostasis assessment was normal. A diagnosis was made of BHD induced by enoxaparin and the patient's treatment was switched to apixaban, resulting in a favourable outcome with resolution of the lesions within 15 days. Case 2: a 71-year-old woman hospitalised for pulmonary embolism was given tinzaparin. At two months of treatment, haemorrhagic bullae were observed on her forearms at distance from the injection sites. A diagnosis of BHD induced by tinzaparin was made. Treatment with tinzaparin was continued and the lesions resolved within 15 days. Heparin-induced BHD is a rare entity initially described in 2006. Ninety-five cases of heparin-induced BHD have been reported. It is characterized by multiple haemorrhagic bullae at a distance from the injection sites. Time to onset of lesions after heparin initiation ranges from 24h to 4 months. Laboratory assessment should be routinely performed to rule out any haemostasis disorders. Lesions subside within 15 days whether heparin is continued or withdrawn. Heparin-induced BHD is a rare but benign side effect of heparins. In the absence of recommendations, therapeutic management should be adapted to the individual situation.

Sections du résumé

BACKGROUND BACKGROUND
Bullous haemorrhagic dermatosis (BHD) induced by heparin is a rare and benign side effect of which we report two cases.
PATIENTS AND METHODS METHODS
Case 1: an 81-year-old man presented haemorrhagic bullae on the limbs and trunk 7 days after starting enoxaparin. The laboratory haemostasis assessment was normal. A diagnosis was made of BHD induced by enoxaparin and the patient's treatment was switched to apixaban, resulting in a favourable outcome with resolution of the lesions within 15 days. Case 2: a 71-year-old woman hospitalised for pulmonary embolism was given tinzaparin. At two months of treatment, haemorrhagic bullae were observed on her forearms at distance from the injection sites. A diagnosis of BHD induced by tinzaparin was made. Treatment with tinzaparin was continued and the lesions resolved within 15 days.
DISCUSSION CONCLUSIONS
Heparin-induced BHD is a rare entity initially described in 2006. Ninety-five cases of heparin-induced BHD have been reported. It is characterized by multiple haemorrhagic bullae at a distance from the injection sites. Time to onset of lesions after heparin initiation ranges from 24h to 4 months. Laboratory assessment should be routinely performed to rule out any haemostasis disorders. Lesions subside within 15 days whether heparin is continued or withdrawn.
CONCLUSION CONCLUSIONS
Heparin-induced BHD is a rare but benign side effect of heparins. In the absence of recommendations, therapeutic management should be adapted to the individual situation.

Identifiants

pubmed: 32005507
pii: S0151-9638(19)31074-9
doi: 10.1016/j.annder.2019.08.021
pii:
doi:

Substances chimiques

Anticoagulants 0
Enoxaparin 0
Tinzaparin 7UQ7X4Y489

Types de publication

Case Reports Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

446-450

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

A Gérard (A)

Service de dermatologie, hôpital Claude-Huriez, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France. Electronic address: berylambre@hotmail.fr.

M Levavasseur (M)

Service de dermatologie, hôpital Claude-Huriez, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France.

L Gaboriau (L)

Service de pharmacologie, CHU de Lille, Centre régional de pharmacovigilance, 59000 Lille, France.

M Stichelbout (M)

Laboratoire d'anatomie et de pathologie, centre de biopathologie, CHU de Lille, 59000 Lille, France.

D Staumont-Salle (D)

Service de dermatologie, hôpital Claude-Huriez, CHU de Lille, 59000 Lille, France; Université de Lille, 59000 Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH